Cyclodextrins as pharmaccutical solubilizers

被引:1514
作者
Brewster, Marcus E.
Loftsson, Thorsteinn
机构
[1] Janssen Pharmaceut, Johnson & Johnson Pharmaceut Res & Dev, B-2340 Beerse, Belgium
[2] Univ Iceland, Fac Pharm, IS-107 Reykjavik, Iceland
关键词
cyclodextrin; toxicology; regulatory status; solubility; stability constants; phase-solubility; supersaturation; additives;
D O I
10.1016/j.addr.2007.05.012
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cyclodextrins are useful functional excipients that have enjoyed widespread attention and use. The basis for this popularity from a pharmaceutical standpoint, is the ability of these materials to interact with poorly water-soluble drugs and drug candidates resulting in an increase in their apparent water solubility. The mechanism for this solubilization is rooted in the ability of cyclodextrin to form non-covalent dynamic inclusion complexes in solution. Other solubilizing attribute may include the ability to form non-inclusion based complexes, the formation of aggregates and related domains and the ability of cyclodextrins to form and stabilize supersaturated drug solutions. The increase in solubility also can increase dissolution rate and thus improve the oral bioavailability of BCS Class II and IV materials. A number of cyclodextrin-based products have reached the market based on their ability to camouflage undesirable physicochemical properties. This review is intended to give a general background to the use of cyclodextrin as solubilizers as well as highlight kinetic and thermodynamic tools and parameters useful in the study of drug solubilization by cyclodextrins. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:645 / 666
页数:22
相关论文
共 221 条
[1]   Spectroscopic studies on the inclusion complex of 2-naphthol-6-sulfonate with β-cyclodextrin [J].
Abdel-Shafi, Ayman Ayoub .
SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY, 2007, 66 (03) :732-738
[2]   Changes in the conformational structure, microscopic and macroscopic pKas of meloxicam on complexation with natural and modified cyclodextrins [J].
Abdoh, A. A. ;
El-Barghouthi, M. I. ;
Zughul, M. B. ;
Davies, J. E. ;
Badwan, A. A. .
PHARMAZIE, 2007, 62 (01) :55-59
[3]   Multimodal inclusion complexes of ampicillin with β-cyclodextrins in aqueous solution [J].
Aki, H ;
Niiya, T ;
Iwase, Y ;
Kawasaki, Y ;
Kumai, K ;
Kimura, T .
THERMOCHIMICA ACTA, 2004, 416 (1-2) :87-92
[4]   Sildenafil/cyclodextrin complexation:: Stability constants, thermodynamics, and guest-host interactions probed by 1H NMR and molecular modeling studies [J].
Al Omari, Mahmoud A. ;
Zughul, Mohammad B. ;
Davies, J. Eric D. ;
Badwan, Adnan A. .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2006, 41 (03) :857-865
[5]  
ALVIRA E, 2000, RECENT RES DEV CHEM, V1, P89
[6]   A THEORETICAL BASIS FOR A BIOPHARMACEUTIC DRUG CLASSIFICATION - THE CORRELATION OF IN-VITRO DRUG PRODUCT DISSOLUTION AND IN-VIVO BIOAVAILABILITY [J].
AMIDON, GL ;
LENNERNAS, H ;
SHAH, VP ;
CRISON, JR .
PHARMACEUTICAL RESEARCH, 1995, 12 (03) :413-420
[7]   Inclusion compounds of psychotropic agents and cyclodextrins [J].
Andronati, SA ;
Shapiro, YE ;
Yakubovskaya, LN ;
Gorbatyuk, VY ;
Andronati, KS ;
Krasnoschekaya, SP .
JOURNAL OF INCLUSION PHENOMENA AND MOLECULAR RECOGNITION IN CHEMISTRY, 1996, 24 (1-2) :175-186
[8]  
[Anonymous], 1983, PHARMACOMETRICS
[9]  
[Anonymous], PHYS DESK REF
[10]  
ANTLSPERGER G, 1992, MINS 6 INT S CYCL, P277